Neuroendocrine Tumors - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 422 pages report, published by Global Markets Direct

Keywords : Neuroendocrine Tumors Therapeutic Products under Development, Key Players in Neuroendocrine Tumors Therapeutics, Neuroendocrine Tumors Pipeline Overview, Neuroendocrine Tumors Pipeline, Neuroendocrine Tumors Pipeline Assessment

Report ThumbnailJune-2017
Neuroendocrine Tumors - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 30, 24, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Neuroendocrine Tumors, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Neuroendocrine Tumors, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neuroendocrine Tumors - Pipeline by AbbVie Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H1 2017
  • Neuroendocrine Tumors - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Neuroendocrine Tumors - Pipeline by Amgen Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H1 2017
  • Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Neuroendocrine Tumors - Pipeline by Celgene Corp, H1 2017
  • Neuroendocrine Tumors - Pipeline by Cleave Biosciences Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H1 2017
  • Neuroendocrine Tumors - Pipeline by Eisai Co Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Eli Lilly and Company, H1 2017
  • Neuroendocrine Tumors - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Exelixis Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Neuroendocrine Tumors - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Ignyta Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Ipsen SA, H1 2017
  • Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Merck & Co Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by MolMed SpA, H1 2017
  • Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Novartis AG, H1 2017
  • Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H1 2017
  • Neuroendocrine Tumors - Pipeline by Peptron Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Pfizer Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Pharma Mar SA, H1 2017
  • Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Regulaxis SAS, H1 2017
  • Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Tarveda Therapeutics Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd, H1 2017
  • Neuroendocrine Tumors - Pipeline by Xencor Inc, H1 2017
  • Neuroendocrine Tumors - Dormant Projects, H1 2017
  • Neuroendocrine Tumors - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Neuroendocrine Tumors - Discontinued Products, H1 2017
  • Table of Contents
  • Table of Contents 2
  • Introduction 4
  • Neuroendocrine Tumors - Overview 5
  • Neuroendocrine Tumors - Therapeutics Development 6
  • Neuroendocrine Tumors - Therapeutics Assessment 17
  • Neuroendocrine Tumors - Companies Involved in Therapeutics Development 29
  • Neuroendocrine Tumors - Drug Profiles 52
  • Neuroendocrine Tumors - Dormant Projects 398
  • Neuroendocrine Tumors - Discontinued Products 400
  • Neuroendocrine Tumors - Product Development Milestones 401
  • Appendix 413

Please select a license type

Share

Related Products

Global Markets DirectNeuroendocrine Tumors - Pipeline Review, H1 2017Product ThumbnailNeuroendocrine Tumors - Pipeline Review, H1 2017, Industry ReportProduct #: 828988
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved